Banyu Pharmaceutical Co. Ltd

Msd K.k.

Taiho Pharmaceutical Company Limited

Merck Sharp + Dohme Corp.

Otsuka Pharmaceutical Company, Limited

Takashi Mita

Nobuhiko Kawanishi

Mitsuru Ohkubo

Tetsuya Kato

Toshihiro Sakamoto

Yoshio Ogino

Katsumasa Nonoshita

Yasuhiro Goto

Mark E Layton

Philip E Sanderson

Yoshikazu Iwasawa

Jiabing Wang

Tadashi Shimamura

Hidetomo Furuyama

Yu Onozaki

Toshiyasu Shimomura

Christopher Norbert Johnson

Steven Howard

Takahiro Ogawa

James Edward Harvey Day

Ryo Kato

Takeshi Sagara

Hiroshi Hirai

Akira Naya

Jeffrey David St Denis

Sachie Arai

Kevin J Rodzinak

Michael A Rossi

Hideki Kurihara

Keita Nagai

Hideya Komatani

Mikako Kawamura

John Walter Liebeschuetz

Takashi Hashihayata

Kazuaki Shibata

Kouta Masutani

Risako Miura

Yufu Sagara

James Edward Day

The invention provides a compound of formula (I):

Heterobicyclic compounds for inhibiting the activity of SHP2

The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula Rrepresents a hydrogen atom or an optionally substituted C-Calkyl group; A represents a hydrogen atom, an optionally substituted C-Calkyl group, an optionally substituted C-Calkenyl group, an optionally substituted C-Calkynyl group, an optionally substituted C-Ccycloalkyl group, an optionally substituted C-Caromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with Rand the nitrogen atom bonded thereto; Rrepresents a hydrogen atom or an optionally substituted C-Calkyl group; and B represents an optionally substituted unsaturated heterocyclic group).

1,2,4-triazine-6-carboxamide derivative

The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.

Inhibitors of AKT activity

The present invention relates to a compound of formula I: wherein: Ris a hydrogen atom, F, CN, etc.; Ris CO, SO, etc.; Ris a phenyl which may be substituted; X, X, and Xeach independently CH, N, etc. provided, however, that among X, Xand X, the number of nitrogen is 0 or 1; W is the following residue: wherein: W, W, and Weach independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof. 

Aminopyridine derivatives having aurora a selective inhibitory action

The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancer 

Substituted [1,2,4]triazolo[4',3&#x2032;:1,6]pyrido[2,3-b]pyrazines of the formula D

The present invention relates to a compound of general formula I: wherein:

The present invention relates to a compound of formula I:  

Aminopyridine derivatives having aurora A selective inhibitory action

The present invention relates to a compound represented by the general formula (I): wherein mand mare 1, 2, or 3; nand nare 0 or 1; i is an integer of any of 1 to m; j is an integer of 1 to m; R is aryl, heteroaryl, or cycloalkyl any of which may be substituted; Rand R' is hydrogen atom, etc. and Rand R&#x2032; is hydrogen atom, etc.; R, R, and Rare hydrogen atom, etc; Xis CH, CX, or N; Xis CH, N, etc.; Xis CH, N, etc.; Xis CH or N; Y, Y, and Yare each independently CH or N; Zand Zare each independently CH or N; W is a 5-membered aromatic heterocyclic group such as pyrazolyl, thiazolyl, etc., or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition or antitumor agent containing the same; and combinations of the antitumor agent with other antitumor agent(s).

The present invention relates to a compound represented by Formula [I]: wherein

Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton

Aminopyridine derivatives having Aurora A selective inhibitory action

Growing community of inventors

Tsukuba, Japan

Takashi Mita